IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3907
Positioning
Market Dominance
Manufacturing
Medical Equipment
$1.7B
John C.M. Farquhar
We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. Our principal executive offices are located in Mountain View, California.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$HTFL Heartflow, Inc. | 37 | 54 | 50 | 24 | - | - | -79.9% | -55.8% | 76.5% | -32.6% | -109.9% | 40.5% | 0.0% | 43.0x | $1.7B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Heartflow, Inc. (HTFL) receives a "Avoid" rating with a composite score of 37.0/100. It ranks #3907 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
John C.M. Farquhar
Chief Executive Officer
Labor Force
699
54
24
31
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for HTFL
Lagging peers — losers tend to keep underperforming
Fair valuation relative to peers
Average quality profile
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for HTFL.
View All RatingsInsufficient data for Financial Analysis
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 54 | 43 | +11ALPHA |
| MOMENTUM | 24 | 5 | +19ALPHA |
| VALUATION | 50 | 29 | +21ALPHA |
| INVESTMENT | 24 | 9 | +15ALPHA |
| STABILITY | 31 | 10 | +21ALPHA |
| SHORT INT | 19 | 4 | +15ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -79.9% (sector -2.5%)
GM 77% vs sector 43%, OM -33% vs sector 1%
Capital turnover N/A, R&D intensity 36.0%
Rev growth 41%
Interest coverage -1.5x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags Heartflow, Inc. with an Avoid rating, assigning a composite score of 37.0/100 and 1 out of 5 stars. Ranked #3907 of 7,333 stocks, HTFL falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
With a quality score of 54/100, HTFL shows adequate but unremarkable business quality. The company reports a return on equity of -79.9% (sector avg: -2.5%), gross margins of 76.5% (sector avg: 42.5%), net margins of -109.9% (sector avg: -0.2%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
HTFL's value score of 50/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/B ratio of 8.40x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
Heartflow, Inc.'s investment score of 24/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 40.5% vs. a sector average of 5.9% and a return on assets of -55.8% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
Heartflow, Inc. is experiencing notably weak momentum with a score of just 24/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at 40.5% year-over-year, while a beta of 2.50 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
HTFL's stability score of 31/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 2.50 and a debt-to-equity ratio of 43.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
Heartflow, Inc.'s short interest score of 19/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include high market sensitivity (beta: 2.50), elevated leverage (D/E: 43.00x), small-cap liquidity risk. At $1.7B (small-cap), HTFL carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Heartflow, Inc. is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3907 of 7,333 overall (47th percentile). Key comparisons include ROE of -79.9% trailing the -2.5% sector median and operating margins of -32.6% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While HTFL currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Short Int. (19) would have the largest impact on the composite score.
ROE 3122% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 80% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 2629% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate Heartflow, Inc. (HTFL) as Avoid with a composite score of 37.0/100 at a current price of $22.70. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in quality (54th percentile) and value (50th percentile), which together account for the majority of the composite score. Offsetting weakness in momentum (24th percentile) and investment (24th percentile) tempers our overall conviction. We assign a Narrow Moat rating (41/100), High uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; sustainability of the current growth rate; the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Heartflow, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 37.0/100 places it at rank #3907 in our full 7,333-stock universe. At $1.7B in market capitalization, Heartflow, Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 41%, though momentum at the 24th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 77% (+34.0pp vs sector) narrow to operating margins of -33% (-33.9pp vs sector) and net margins of -109.9%, yielding a gross-to-net conversion rate of -144%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $22.70, Heartflow, Inc. is trading near fair value based on current fundamentals. Our value factor score of 50/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at P/B of 8.4x, P/S of 11.6x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 77% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Revenue growth of 41% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
The Avoid rating (composite 37.0/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Thin net margins of -109.9% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
Weak momentum (24th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
We assign a High uncertainty rating to Heartflow, Inc.. Key risk factors include elevated market sensitivity (beta of 2.50), current negative profitability (net margin -109.9%), below-average price stability (31th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: elevated market sensitivity (beta of 2.50); current negative profitability (net margin -109.9%); below-average price stability (31th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 31th percentile and quality factor at the 54th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 77% provide a buffer against cost pressures. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate Heartflow, Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-79.9%), negative profitability, weak asset returns (ROA -55.8%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Heartflow, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Heartflow, Inc. receives a Avoid rating with a composite score of 37.0/100 (rank #3907 of 7,333). Our quantitative framework assigns a Narrow Moat (41/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 37/100.
Our analysis does not support a constructive view on Heartflow, Inc. at this time. The combination of the current quantitative profile, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We assign Heartflow, Inc. a Narrow Moat rating with a composite moat score of 41/100. The company possesses identifiable competitive advantages, though they are less entrenched than those of wide-moat peers. Our analysis indicates that Heartflow, Inc. can sustain above-average returns on invested capital for at least 10 years, with the strongest contributor being growth durability at 13/20.
The strongest moat sources are growth durability (13/20) and margin superiority (10.2/20). Rev growth 41%. GM 77% vs sector 43%, OM -33% vs sector 1%. These pillars form the core of Heartflow, Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (2.5/20) and reinvestment efficiency (7/20). ROE proxy -79.9% (sector -2.5%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Heartflow, Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 77% providing a solid profitability foundation, robust top-line growth of 41% expanding the revenue base. The margin cascade from 77% gross to -33% operating to -109.9% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality is adequate though not exceptional, with the quality factor at the 54th percentile.
The margin profile shows gross margins of 77%, operating margins of -33%, net margins of -109.9%. Return metrics include ROE of -79.9% and ROA of -55.8%. Relative to the Manufacturing sector, gross margins are 34.0 percentage points above the sector median of 43%, and ROE of -79.9% compares to a sector median of -2.5%.
The balance sheet reflects moderate leverage with D/E of 43%, revenue growth of 41%. The sector median D/E is 0%, putting Heartflow, Inc. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
High beta of 2.50 means amplified losses in market selloffs — in a broad market correction, this stock would likely decline more than the index.
Above 50MA
37.18%
Net New Highs
+51081

HeartFlow director Jeffrey Lightcap purchased 40,000 shares worth $1.05 million on December 16, 2025, just after the stock hit a 52-week low of $25.38. While the company shows strong revenue growth of 41% year-over-year in Q3, it faces significant profitability challenges with net losses expanding to $50.9 million. The insider buy suggests confidence in the company's future, but the stock remains risky for investors given its recent IPO status and limited public company track record.
MOUNTAIN VIEW, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Morgan Stanley Technology, Media & Telecom Conference. The presentation will take place in San Francisco, CA, on Tuesday, March 3, 2026, at 10:45 a.m. PT / 1:45 p.m. ET. A live and archived version of the fireside chat will be available on t